This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Journalology/ Peer Review/ Authorship  • Medical Practice  • Medical Ethics  • Neurology  • Alzheimer Disease  • Cognitive Disorders  • Statistics and Research Methods  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: The study by Drs Psaty and Kronmal¹ and the accompanying Editorial by Drs DeAngelis and Fontanarosa² regarding rofecoxib illustrate the recurring problem of discretionary or data-driven analysis. Given the possibility of selective analysis based on observed data and the risk of positive results due to chance alone, it is critical to know in detail which analyses were prespecified and when the prespecification occurred. This can only be done via a full protocol repository, as we suggested in 2002.³ Our proposal would establish a secure real-time repository for protocols, amendments, and statistical analysis plans. The material would be kept confidential for intellectual property reasons during the clinical trial and its analysis and then made public at the time of publication. The proposal has yet to be implemented, although the Food and Drug Administration (FDA) Act of 2007 (US HR3580), which provides for a Web site for results of . . . [Full Text of this Article]

Kent R. Johnson, MD
kent.johnson@newcastle.edu.au
Department of Clinical Pharmacology
University of Newcastle
Carlton, Australia

Marissa N. D. Lassere, MBBS, PhD
Department of Rheumatology
St George Hospital
Sydney, Australia

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?